Article

Meeting Demands Of Accelerated Timelines Using Solid Form Screening And Rapid Formulation Selection

Source: Lonza
GettyImages-1327624070-lab-research-development

Several factors in the pharmaceutical industry are driving the need to reduce the development time from concept to Phase 1 trials. This includes funding models, market competition, and a focus on small targeted populations. Increasingly complex drug compounds, such as specialized products and orphan medications, are exacerbating this by calling on specialized skill sets and technologies to meet target product profiles. With 63% of all new prescription drugs in the last five years coming from small biotechs1, the need for external partners is on the rise.

As a result, it is more important than ever to find a qualified CDMO that can streamline the development pathway, particularly for APIs with challenging properties such as complex syntheses, challenging physical properties, and/or low aqueous solubility and poor bioavailability. That is why Lonza has developed its integrated service package, SimpliFiH® Solutions, which offers a combination of targeted testing and basic scientific principles to accelerate development of a preferred synthetic route, a progressible solid form, and a commercially viable formulation in early drug development.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online